Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Functional Magnetic Resonance Imaging	NCIT_C17958	[The principle of functional MRI imaging is to take a series of images of an organ in quick succession and to statistically analyze the images for differences among them. Most commonly used in studies of brain function.]
Immunomodulator OHR/AVR118	NCIT_C49092	[A broad-spectrum peptide nucleic acid formulation comprised of breakdown products of casein, peptone, RNA and serum albumin, with potential anti-inflammatory, immunomodulatory, anti-anorectic and anti-cachexia activities. AVR118 mainly contains two peptides, peptide A and peptide B, in approximately a 1:1 ratio: peptide A (31 a. a.) is derived from bovine casein; peptide B (21 a. a.) is covalently linked via phosphodiester bond to a diadenosine unit. In addition, AVR118 contains nucleosides, nucleoside diphosphates and nucleoside monophosphates. Upon subcutaneous injection of AVR118, this agent affects the synthesis of many pro-inflammatory chemokines and cytokines, especially monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-8, IL-1 beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha). In particular, AVR118 stimulates macrophages to produce these mediators while in highly activated macrophages this agent inhibits their synthesis. This way, AVR118 may prevent the excessive release of cytokines seen during chemotherapy. Controlling the release of pro-inflammatory mediators may ultimately improve appetite and mood, increase strength and weight gain, and decrease fatigue.]
Fluorothymidine F-18	NCIT_C49093	[A radioconjugate consisting of a thymidine analogue radiolabeled with fluorine F 18, a positron emitting isotope. Phosphorylated by S-phase-specific thymidine kinase 1, 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) is trapped intracellularly by entering the salvage pathway of DNA synthesis without incorporation into DNA. 18F-FLT serves a marker of tumor cell proliferation for imaging with positron emission tomography (PET); as a marker of proliferation rather than metabolism, it is more specific to tumor tissue than 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG). This agent is metabolically stable, accumulates in the normal bone marrow and the liver, and does not cross the blood-brain barrier.]
Neratinib	NCIT_C49094	[An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.]
HER2 Inhibitor	NCIT_C159156	[Any agent that inhibits the human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).]
JNK Inhibitor CC-401	NCIT_C49095	[A second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. Based on the chemistry of SP600125, another anthrapyrazolone inhibitor of JNK, CC-401 competitively binds the ATP binding site of JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of transcription factor c-Jun; decreased transcription activity of c-Jun; and a variety of cellular effects including decreased cellular proliferation.]
Mitogen-Activated Protein Kinase Inhibitor	NCIT_C2149	[Any substance that inhibits mitogen-activated protein kinase (MAPK), an enzyme that catalyzes the addition of a phosphate group to a protein in the cell proliferation signaling pathway in response to external stimuli. Inhibition of mitogen-activated protein kinase can result in the inhibition of cell proliferation.]
Neoplastic Epithelioid Fibrohistiocytic Cell	NCIT_C49080
Neoplastic Connective and Soft Tissue Epithelioid Cell	NCIT_C43307
Melanoma of the Ciliary Body and Choroid pT1 TNM Finding v7	NCIT_C88686	[Tumor size category 1. (from AJCC 7th Ed.)]
Melanoma of the Ciliary Body and Choroid Pathologic Primary Tumor TNM Finding v7	NCIT_C88683	[A pathologic finding about one or more characteristics of melanoma of the ciliary body and choroid, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.]
Melanoma of the Ciliary Body and Choroid pT1a TNM Finding v7	NCIT_C88687	[Tumor size category 1 without ciliary body involvement and extraocular extension. (from AJCC 7th Ed.)]
Melanoma of the Ciliary Body and Choroid pT1b TNM Finding v7	NCIT_C88688	[Tumor size category 1 with ciliary body involvement. (from AJCC 7th Ed.)]
Melanoma of the Ciliary Body and Choroid pT1c TNM Finding v7	NCIT_C88689	[Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)]
Mixed Bacteria Vaccine	NCIT_C74063	[A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12).]
MVA-PSA/PAP Prostate Cancer Vaccine	NCIT_C74064	[A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding genes for prostate specific antigen (PSA) and prostate acid phosphatase (PAP) with potential immunostimulatory and antineoplastic activities. Upon administration, MVA-PSA-PAP prostate cancer vaccine expresses PSA and PAP peptides, which may elicit humoral and cellular immune responses against prostate cancer cells expressing PSA and PAP. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy.]
Vaccinia Vaccine	NCIT_C2313	[A class of antineoplastic vaccines containing the vaccinia virus, originally used for immunization against smallpox, as a viral vector and immunogenic substance.]
Nanoparticle Albumin-Bound Rapamycin	NCIT_C74065	[The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.]
NY-ESO-1/LAGE-1 Peptide Vaccine	NCIT_C74066	[A cancer vaccine containing HLA class I- and II-binding peptides derived from the NY-ESO-1/LAGE-1 cancer/testis antigen with potential immunostimulatory and antineoplastic activities. Upon administration, NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine may induce a cytotoxic immune response against tumor cells that over-express NY-ESO-1/LAGE-1. Rarely expressed by normal cells, the NY-ESO-1/LAGE-1 cancer/testis antigen has been shown to be preferentially expressed on the surface of some cancer cell types.]
MET Tyrosine Kinase Inhibitor BMS-777607	NCIT_C74060	[An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.]